MedTrace Logo

Cannabis and Opioid Use Disorder, Study 2

NCT07661446 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-08-20

No results posted yet for this study

Summary

This inpatient study enrolls healthy individuals who have opioid use disorder. Participants live at the University of Kentucky Hospital for approx. 6 weeks. During this time, we will examine how repeated doses of oral cannabis and acute doses of oral and inhaled cannabis 1) modify the intensity and time course of opioid withdrawal, 2) modify the effects of intranasal opioid administration and 3) impact the safety of opioid administration.

Conditions

  • Opioid Use Disorders
  • Cannabis Use

Interventions

DRUG

Inhaled Cannabis

Participants will receive inhaled cannabis and placebo

DRUG

Intranasal Opioid

Participants will receive intranasal opioids and placebo

Sponsors & Collaborators

  • University of Kentucky

    lead OTHER

Principal Investigators

  • Shanna Babalonis, PhD · University of Kentucky College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2029-07-30
Completion
2030-01-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07661446 on ClinicalTrials.gov